5-ethyl-2-(5-hydroxypent-2-ynoxy)-3H-pyrano[2,3-d]pyrimidine-4,7-dione | 915212-48-5

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 吡喃嘧啶类
• 英文名称: 5-ethyl-2-(5-hydroxypent-2-ynoxy)-3H-pyrano[2,3-d]pyrimidine-4,7-dione
• CAS: 915212-48-5
• 化学式: C₁₄H₁₄N₂O₅
• 分子量: 290.276
• InChiKey: QXYQGNQCGMRZCT-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  0.1
• 重原子数：
  21
• 可旋转键数：
  4
• 环数：
  2.0
• sp3杂化的碳原子比例：
  0.36
• 拓扑面积：
  97.2
• 氢给体数：
  2
• 氢受体数：
  6

反应信息

• 作为产物：
  描述：

  5-ethyl-2-methylsulfanyl-3h-pyrano[2,3-d]pyrimidine-4,7-dione 在 sodium hydride 、 间氯过氧苯甲酸 作用下， 以 四氢呋喃 、 二氯甲烷 、 N,N-二甲基甲酰胺 为溶剂， 生成 5-ethyl-2-(5-hydroxypent-2-ynoxy)-3H-pyrano[2,3-d]pyrimidine-4,7-dione
  参考文献：
  名称：

  SAR studies of C2 ethers of 2H-pyrano[2,3-d]pyrimidine-2,4,7(1H,3H)-triones as nicotinic acid receptor (NAR) agonist

  摘要：

  Based on in house screening lead compound 1 for the NAR project, SAR studies have been focused on the modification of the C2 ethers of the pyrimidinedione core structure. In this effort, an unpredictable SAR trend was overcome in the alkyl ether and arylalkyl ether series to identify compound 24 with improved in vitro activity compared to nicotinic acid. More consistent and predictable SAR was achieved in the propargyl ether series. Lead compound 41 was identified with good in vitro and in vivo activity in rat, and much improved rat PK profile. (C) 2011 Elsevier Ltd. All rights reserved.

  DOI：

  10.1016/j.bmcl.2011.12.041

文献信息

• NITROGEN-CONTAINING HETEROCYCLIC COMPOUNDS AND METHODS OF USE THEREOF
  申请人：Palani Anandan

  公开号：US20080019978A1

  公开（公告）日：2008-01-24

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: and L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

  本发明提供了式（I）的化合物及其药学上可接受的盐，溶剂化合物，酯和互变异构体，其中： Q选自以下组： L选自以下组： 本发明还提供了包含一种或多种式（I）化合物的药学组合物以及使用式（I）化合物的方法。
• Nitrogen-containing heterocyclic compounds and methods of use thereof
  申请人：Palani Anandan

  公开号：US20070066630A1

  公开（公告）日：2007-03-22

  The present invention provides compounds of Formula (I): and pharmaceutically acceptable salts, solvates, esters, and tautomers thereof, wherein: Q is selected from the group consisting of: L is selected from the group consisting of: pharmaceutically compositions comprising one or more compounds of formula (I), and methods of using the compounds of formula (I).

  本发明提供了式（I）化合物及其药学上可接受的盐、溶剂化合物、酯和互变异构体，其中：Q选自以下组：L选自以下组：包括一种或多种式（I）化合物的药学组合物，以及使用式（I）化合物的方法。
• US7723342B2
  申请人：——

  公开号：US7723342B2

  公开（公告）日：2010-05-25
• US7737155B2
  申请人：——

  公开号：US7737155B2

  公开（公告）日：2010-06-15
• US7750015B2
  申请人：——

  公开号：US7750015B2

  公开（公告）日：2010-07-06